To determine the effect of prolonged suppressive acyclovir therapy on the antibody response to herpes simplex virus type 2 (HSV-2) proteins, we studied sequential sera from 33 patients with frequently recurring (six or more recurrences per year) genital herpes.
Studies of herpes simplex virus (HSV) infections in animals have shown that humoral immunity plays an important role in resistance to viral challenge [1-4], spread of virus to neuronal sites
, and maintenance of latency [8, 9] . In humans, pre-existing antibody to HSV is associated with less-severe first episodes of genital herpes [10, 11] . Previous work using radioimmunoprecipitation and immunoblotting has demonstrated that there is a sequential antibody response to HSV-specified proteins after primary genital HSV type 2 (HSV-2) infection in humans [12] . Major immunogens have been identified and include glycoproteins gB, gG, gC, gE, and gD and a phosphoprotein, VP16 [12, 13] .
When individuals with primary genital HSV infection are treated with the acyclic nucleoside acyclovir, seroconversion to major HSV proteins and the development of neutralizing antibody are delayed [14, 15] . Analyses using immunoblotting have shown that the amounts of antibodies that are made to individual proteins are decreased when compared with those from placebo recipients [16, 17] , In addition, lower titers of antibodies to VP16 and gD during the primary episode are associated with more-severe symptoms during the first untreated recurrence [12] .
Acyclovir, when administered chronically to individuals with frequently recurring genital HSV disease, is highly effective in suppressing recurrent episodes [18] [19] [20] [21] 22 ]. These observations have given rise to concerns that suppressive therapy may alter the patient's long-term disease course by diminishing levels of antibodies that are important in limiting the disease. To determine the effect of chronic acyclovir administration on the antibody response to HSV proteins, we evaluated sequential sera from a cohort of patients with severe genital HSV disease who had been treated daily with acyclovir or placebo for one year. We analyzed the severity of recurrent episodes after cessation of therapy to determine whether there is a relation between clinical expression of disease and relative antibody titers.
Patients and Methods
Patients. Ninety patients with frequently recurring (six or more recurrences in the year before enrollment) were enrolled in a placebo-controlled trial of oral acylovir (Zovirax?; Burroughs Wellcome, Research Triangle Park, NC) for the prevention of recurrent genital herpes. Thirty-three of these patients (seven women, 26 men) had sera drawn at enrollment and at six and 12 months after initiating therapy and were, therefore, included in the study described here. All were shown before entry to have culture-proven, genital HSV-2 disease. Twenty-two (seven women, 15 men) received 400 mg of oral acyclovir and 11 men received placebo twice daily for one year. Patients were seen monthly in the University of Washington Viral Disease Clinic at Harborview Medical Center (Seattle) during the year of therapy and through the first two recurrences after discontinuing therapy. Patients also reported to the clinic when symptoms of genital HSV recurrences developed. Sera were drawn, genital examinations were performed, and specimens for virus culture were taken from genital lesions (if present), the cervix (women), and urethra (men) at each clinic visit.
Immunoblot analysis of sera. Human diploid fibroblasts (HET line) were infected with HSV-2 strain 333 and lysed as previously described [23] . Solubilized proteins were separated by polyacrylamide gel electrophoresis, transferred to nitrocellulose, and reacted with serum antibodies, as previously described [24] . Antibodies were detected by enzyme immunoassay as described in detail previously [23] .
Reactive proteins on the immunoblots were previously identified by immmunoprecipitation using monoclonal antibodies directed against the major HSV-2 proteins [16] . The proteins that were identified on densitometry tracings and analyzed in this study included gB, gG (the 92 000 molecular weight species [25, 26] ), gD, and VP16. The proteins gC and gE closely comigrate in this immunoblot system and were analyzed together as the gCgE complex.
Sera were tested for rubella antibody by using passive HA (Abbott Laboratories, North Chicago, 111) and for CMV antibody by a slide agglutination test (Becton Dickinson, Lincoln Park, NJ).
Study design. Sera drawn at enrollment, at six and 12 months after initiating acyclovir, and acute and convalescent sera (drawn at the first recurrence after therapy was completed) were analyzed using an immunoblot.
The intensity of staining of bands on immunoblots may vary with different lysate preparations and with immunodetection from assay to assay. To minimize this variability in the analyses and to allow direct comparison among results derived from sera from the same patient, we tested, together, sequential sera from an individual patient by using strips originating from the same gel. Thirty-two patients had sufficient sera that could be evaluated in this manner. In addition, to allow comparison of sera drawn at a particular time point from patient to patient, we analyzed all of the 33 patients' sera from a single time point (enrollment, six months, or 12 months) together by testing the sera using strips derived from a single gel for each time point.
Results
Clinical characteristics of patients. Twenty-two patients received acyclovir for one year. Of the 22, 15 (68^0) were men. The mean age of the group was 35 y (range, 25-49 y). The mean number of recurrences per year before enrollment was 13 (range, 7-30). Sixteen patients experienced breakthrough recurrences while receiving acyclovir. The mean number of breakthrough recurrences was two (range, 0-6).
The mean age of the 11 men who received placebos was 34. Their mean number of recurrences before therapy was 10 (range, 6-14) and during treatment, eight (range, 2-16).
Analysis of sequential sera. The immunoblots from the 32 individual patients who were tested indicate that although most patients had substantial levels of antibodies at enrollment, a pronounced decrease in the amount of staining was apparent in the six-and 12-month sera of patients receiving suppressive acyclovir ( figure 1, left) . Recipients of placebo, as a group, did not have similar decreases (figure 1, right).
The distribution of peak heights of densitometry tracings from sera drawn at enrollment and after 12 mo of acyclovir or placebo are shown in figure 2. Considerable variation in absolute levels of antibodies among both placebo-and acyclovir-treated patients were noted at enrollment and at six (data not shown) and 12 months after enrollment. Peak heights for antibodies to gB, gG, gCgE, and VP16 did not differ significantly between recipients of acyclovir or placebo at enrollment (Wilcoxon's rank sum test). Placebo-treated individuals had, however, signifi- NOTE. Sera were tested for rubella antibody and CMV antibody as described in Patients and Methods. * Peak heights were determined from densitometry tracings. Measurements for gB, gG, gCgE, VP16, and gD were added to estimate total antibody levels.
antibodies in the placebo recipients for gB (P = .01), gG (P < .01), gCgE (P < .05), VP16 (P < .01), and gD (P < .02). After 12 mo of treatment, the levels of antibodies to HSV-2 proteins remained lower for gG (P < .01), gCgE (P < .01), VP16 (P < .05), and gD (P < .01). Levels of antibody to gB in recipients of acyclovir or placebo, however, were not significantly different.
Effect of acyclovir on antibody levels to cytomegalovirus (CMV) and rubella. Levels of antibodies to CMV and to rubella were also tested in recipients of acyclovir, all of whom had reduced levels of "total" antibody to HSV-2 at six and 12 months after the onset of therapy (table 1) Correlating antibody decreases and clinical prameters of disease. To determine whether the manitude of decrease in antibody levels during one yer of acyclovir treatment had an effect on the coure of disease during and after therapy, we evaluated te relation between clinical parameters and the pek height for each antibody and for "total" antibody episodes during therapy influenced the antibody response to HSV-2 proteins, we compared the means of the rados of 12.mo antibody leveis to enrollment antibody levels m the 15 assessable patients who had breakthrough episodes and the six who did not. There were no significant differences in the mean ratios of antibody levels between the two groups (Spearman's rank correlation coefficient), a result suggesting that the occurrence of breakthrough episodes did not affect antibody levels, Reconstitution of antibody levels after an untreated recurrence. To determine how a single symptomatic recurrence, which occurred after therapy was discontinued, influenced the antibody response to HSV-2 proteins, we compared the antibody levels in sera that were obtained 18-28 d (convalescent sera) after the first recurrence after therapy with the corresponding levels in sera obtained at the end of suppressive therapy. Antibody levels in convalescent sera after the first recurrence after therapy equaled or exceeded the corresponding levels in 12-mo sera in 18 (86^0) of 21 patients for gB, 14 (67^o ) of 21 for gG, 16 (76^o) of 21 for gCgE, 17 (81^o) of 21 for VP16 and gD. When levels in convalescent sera were compared with those in enrollment sera (figure 4) , however, 15 (71^o) of 21 patients had peak heights less than those generated by enrollment sera for gB, gG, and gCgE; 11 (52^o) of 21 for VP16; and 14 (67^o) of 21 for gD. Thus, in most patients, a single recurrence resulted in an increase in antibody level but was insufficient to reconstitute antibodies to levels before therapy, Five patients, including one whose antibody titers Correlation of absolute antibody levels with disease severity. To determine whether there was a relation between the absolute amount of antibody to HSV-2 proteins at the end of acyclovir treatment and subsequent time to and severity of the first recurrence, we compared peak heights of the absolute antibody levels with parameters of severity of disease after cessation of therapy. There were 19 acyclovirtreated patients on whom posttherapy recurrence data were available. Their 12-mo sera were assayed together on strips derived from a single gel, and median peak heights were determined for each protein. Significant differences in time to first recurrence and duration of lesions were not detected between patients with less than median peak heights versus those with greater than median peak heights (table 2). The mean duration of pain in the first recurrence after therapy in individuals whose antibody levels to gB were lower than the median value was significantly shorter, however, than the mean duration of pain in individuals whose antibody levels to gB were greater than the median (1.1 ? 0.9 d vs. 2.9 ? 3 .0 d; P = .04).
There was a trend towards a shorter duration of first recurrence after acyclovir therapy in individuals with antibody levels to gB below the median value compared with those who had levels above the median (8.4 ? 4.5 d vs. 11.5 ? 1.3 d; P = .10; table 2). Patients whose levels of antibody to gB, gCgE, and VP16 were less than the median values had significantly fewer lesions in the first recurrence after therapy than did individuals whose levels of antibodies to these HSV-2 proteins were higher than the median values (table 3) . These data suggest that high levels of antibody to gB (and possibly other HSV-2 proteins) may be associated with more-severe first recurrences after therapy.
Discussion
We have used western blot analysis of sera from patients receiving daily acyclovir for one year to demonstrate that levels of antibodies to HSV-2 proteins decline over the course of therapy. We could not, however, detect a correlation between the magnitude of decrease and parameters of clinical disease severity either during or after therapy. Further, our data suggest that relatively high absolute levels of antibodies to gB (and possibly other major HSV-2 proteins) at the end of a year of acyclovir therapy may be associated with a more-severe first recurrence after therapy. Finally, we have shown that a single clinical recurrence after therapy is insufficient, in most cases, to reconstitute the antibody to the levels before therapy.
A consistent decrease in antibody levels to HSV-2 proteins occurred in individuals receiving acyclovir for one year. It is likely that the decrease in antibody levels is a result of an overall lower level of antigenic stimulation. Another possible explanation is that acyclovir has a direct suppressive effect on antibody .04 NS NOTE. The number of patients with more than five lesions or with five or fewer lesions were compared with those patients with peak heights greater than the median value calculated for each protein or those with peak heights at or below the median value.
* P values were determined using Fisher's exact test (one tail). NS, not significant. ger measurable rises in levels of antibody to the viruses [11, 27, 28] . We could not demonstrate an association between antibody levels at enrollment and breakthrough recurrences of HSV during suppressive therapy. One explanation for this is that the levels of antibodies in the treated patients were so high that they "saturated" the western blot system and precluded detecting significant changes in amounts of antibodies. Dilution experiments with high titer sera in the western blot system indicated, however, that there is a broad linear range in which densitometry peak heights accurately reflect titer of antibody [16] . In addition, it is possible that changes in levels of antibodies other than those on which we focused were more closely related to the clinical parameters measured. Finally, cellular immune function may play a more important role in mediating severity of disease than does humoral immunity.
In most patients, antibody levels increased after the first recurrence after therapy, although the levels were lower than those measured before treatment. It is possible that levels would be restored in most patients with further antigenic stimulation of a second untreated recurrence, but these sera were unavailable to us for study.
Studies of individuals who were treated with systemic acyclovir during their first episodes of genital HSV have demonstrated that patients with delayed seroconversion to gD and VP16 had initial untreated recurrences that were more severe. Because we had observed that antibody levels declined with acyclovir therapy, we compared absolute amounts of antibodies among patients to determine whether there was a threshold amount of antibody at the end of therapy that might be predictive of a more-severe first recurrence after therapy. We found that higher levels of antibodies to gB were significantly associated with more-severe first recurrences after therapy. This observation may reflect more-frequent subclinical recurrences and greater antigen stimulation during therapy. Alternatively, the severity of HSV recurrences in patients with high levels of antibody to gB may reflect an immunopathological mechanism, as has been suggested by antigen detection studies on patients with HSV-related erythema multiforme [29] .
Although these data on antibody to gB are of interest, it should be noted that the test method is limited in its ability to completely discriminate antibody to gB and gG, because of their partial comigration in gels [16] . Values for gB consist of the height of one peak that is solely gB and a second peak that may contain gG [16] . Thus, the apparent levels of antibody to gB could be affected by "contamination" with antibody to gG. Further, it would be of interest to compare the disease severity of the first recurrence after therapy with that of the recurrent episodes preceding acyclovir treatment in the patients with higher levels of antibody to gB. The apparent association of antibody to gB and disease severity will require further studies, preferably with protein-specific assays.
Anecdotal observations have suggested that patients often have severe "rebound" recurrences after discontinuing prolonged suppressive therapy. It appears that patients with relatively high levels of antibody to gB at the end of therapy may be experiencing such a rebound phenomenon. It is difficult to make specific statements about any one individual's likelihood to have such a rebound, however, as there is great variability in the severity of individual episodes of genital herpes even without therapy [30] . Thus, the available data indicate that although treatment with acyclovir for one year results in depressed antibody levels against HSV-2 proteins, in most cases, this decrease in humoral response does not leave the patients immunologically "unprotected" and susceptible to more-severe first recurrences after cessation of therapy.
